mCSPC
mCSPC
Advertisement
Emily MenendezmHSPC | February 27, 2024
Phase III mHSPC trials can take up to a decade to complete when OS is used as the primary endpoint.
Read More
Katy MarshallmCSPC | February 8, 2024
The addition of apalutamide to ADT should be considered in patients with high-risk BRPC, according to researchers.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | January 30, 2024
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Katy MarshallASCO GU Symposium 2024 | January 23, 2024
Researchers evaluated real-world survival for patients with mCSPC who received enzalutamide or apalutamide treatment.
Katy MarshallmCSPC | December 29, 2023
Researchers noted a lack of research surrounding treatment-related adverse events in these patients.
John Shen, MDmCSPC | December 19, 2023
Drs. Shen and Graff discuss patient outcomes from TITAN and SPARTAN, as well as assessing functional vs chronological age.
Emily MenendezCRPC | November 20, 2023
Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Zachary BessetteESMO 2023 | October 18, 2023
Research shed light on the safety and efficacy of pembrolizumab plus enzalutamide and ADT in patients with NHA-naïve mHSPC.
Emily MenendezASTRO 2023 | October 10, 2023
Investigators used plasma samples from the ORIOLE study to conduct a blind validation study based on this new research.
Emily MenendezmCSPC | October 12, 2023
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Zachary BessetteCRPC | October 31, 2023
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
Zachary BessetteAdvanced Urothelial Carcinoma | August 30, 2023
Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon.
Emily MenendezProstate Cancer | August 23, 2023
The phase 3 TITAN study assigned patients with mCSPC apalutamide or placebo with ADT to determine its effects on PFS and OS.
Emily MenendezmCSPC | October 12, 2023
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
Emily MenendezProstate Cancer | October 12, 2023
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi and Wallis conclude with a breakdown of the right patients for radiotherapy when presenting with de novo mCSPC.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi, Wallis address which patients with mCSPC experience synergistic effects from abiraterone plus radiotherapy.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as an LBA at the ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement